Drilldown: Medicines
Medicines > classes 
:
Antidepressant or
Botanical or
[[:Category:Mast_cell_stabilizers|Mast cell stabilizer]]
:
Antidepressant or
Botanical or
[[:Category:Mast_cell_stabilizers|Mast cell stabilizer]] Use the filters below to narrow your results.
generic:
brand:
None (24) ·
Anafranil (1) ·
Astelin, Astepro (intranasal); Optivar (ophthalmic); with fluticasone as Dymista (1) ·
Aurorix (1) ·
Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) ·
Edronax (1) ·
Fetzima (1) ·
Ludiomil (1) ·
Marplan (1) ·
Nardil (1) ·
Norpramin (1) ·
Parnate (1) ·
Patanol, Pataday (ophthalmic, now OTC), Patanase (intranasal) (1) ·
Savella (1) ·
Serzone (1) ·
Stablon (1) ·
Surmontil (1) ·
Tofranil (1) ·
Valdoxan (1) ·
Vivactil (1) ·
Zaditor, Alaway (ophthalmic, OTC); Zaditen (systemic, outside US) (1) ·
Zoloft (1)
classes: (Click arrow to add another value)
mechanism:
Apomorphine and nuciferine; dopaminergic activity (1) ·
Contains atropine, scopolamine, hyoscyamine (1) ·
Contains bufotenin and DMT (1) ·
Contains harmine, harmaline, tetrahydroharmine (1) ·
Contains ibogaine; kappa-opioid agonist (1) ·
Contains LSA (2) ·
Contains mescaline (2) ·
Contains muscimol and ibotenic acid (1) ·
Contains psilocybin and psilocin (1) ·
Contains salvinorin A (1) ·
DMT + MAOI (harmine/harmaline); 5-HT2A agonist (1) ·
DMT-containing plant used in psychedelic preparations (1) ·
Irreversible non-selective MAO inhibitor (3) ·
Kavalactones; GABAA modulator; sigma receptor activity (1) ·
Mechanism incompletely understood (1) ·
Melatonin receptor agonist; 5-HT2C antagonist (1) ·
Mitragynine/7-hydroxymitragynine; mu-opioid partial agonist (1) ·
Mu-opioid agonist; modulates glutamate AMPA receptors (1) ·
Partial MAOI; anticholinergic effects (1) ·
Partial mu-opioid receptor agonist; alpha-2 agonist (1) ·
Potent mu-opioid receptor agonist (1) ·
Potent serotonin reuptake inhibitor; also NRI (1) ·
Reversible inhibitor of MAO-A (1) ·
Reversible MAO-A inhibitor; beta-carboline (1) ·
Reversible MAO-A inhibitor; NMDA antagonist; beta-carboline (1) ·
Selective norepinephrine reuptake inhibitor (3) ·
Serotonin and norepinephrine reuptake inhibitor (3) ·
Serotonin reuptake inhibitor and 5-HT2A antagonist (1) ·
Serotonin–norepinephrine reuptake inhibition (balanced) (1) ·
Serotonin–norepinephrine reuptake inhibitor (2) ·
TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) ·
Weak serotonin reuptake inhibitor; beta-carboline (1) ·
Weak SRI; primarily H1/D2/alpha antagonist (1) ·
'"`UNIQ--vote-000011D5-QINU`"' Minimal systemic absorption and the dual mechanism underlie its first-line role in seasonal allergic conjunctivitis. Comfort drops without preservatives are available for sensitive patients'"`UNIQ--ref-000011D6-QINU`"'. (1) ·
'"`UNIQ--vote-00001284-QINU`"' Systemic oral ketotifen (available outside US) has historical use for asthma adjunct therapy via the same dual mechanism, but oral use produces sedation and weight gain — the topical ophthalmic application largely avoids both'"`UNIQ--ref-00001285-QINU`"'. (1) ·
'"`UNIQ--vote-000013B1-QINU`"' Topical application minimizes systemic antihistaminic burden; the characteristic bitter taste with nasal use (drainage to oropharynx) is the main tolerability issue'"`UNIQ--ref-000013B2-QINU`"'. (1)
uses:
None (41) ·
Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) ·
'"`UNIQ--vote-000011D7-QINU`"', '"`UNIQ--vote-000011D8-QINU`"' (1) ·
'"`UNIQ--vote-00001286-QINU`"' (1) ·
'"`UNIQ--vote-000013B3-QINU`"', '"`UNIQ--vote-000013B4-QINU`"', '"`UNIQ--vote-000013B5-QINU`"' (1)
starting dose:
None (41) ·
25 mg (1) ·
Intranasal 0.1% or 0.15%: 1-2 sprays/nostril BID; ophthalmic 0.05%: 1 drop in each eye BID (1) ·
Ophthalmic 1 drop in each eye every 8-12 hours (1) ·
Ophthalmic Pataday 0.7%: 1 drop in each eye once daily (24-hour formulation); Patanol 0.1% BID; intranasal Patanase 2 sprays/nostril BID (1)
preparations:
None (41) ·
0.025%, 0.035% ophthalmic solutions (1) ·
0.1% (Patanol), 0.2% (Pataday once-daily original), 0.7% (Pataday 24-hour) ophthalmic solutions; 0.6% nasal spray (1) ·
0.1%, 0.15% intranasal spray; 0.05% ophthalmic solution; combination Dymista (azelastine 0.137 mg + fluticasone 50 mcg/spray) (1) ·
25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1)
fda max:
routes:
onset:
duration:
halflife:
None (40) ·
Not meaningfully described for ophthalmic use'"`UNIQ--ref-00001287-QINU`"' (1) ·
~12 hours (1) ·
~22 hours; longer 54 hours (desmethylazelastine, active metabolite)'"`UNIQ--ref-000013B6-QINU`"' (1) ·
~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1) ·
~3 hours (systemic, when measurable; topical action dominates)'"`UNIQ--ref-000011D9-QINU`"' (1)
bioavailability:
None (40) ·
Absolute bioavailability not precisely characterized; food modestly increases exposure (1) ·
Intranasal ~40% systemic; ophthalmic minimal'"`UNIQ--ref-000013B7-QINU`"' (1) ·
Topical with minimal systemic absorption'"`UNIQ--ref-000011DA-QINU`"' (1) ·
Topical with minimal systemic absorption'"`UNIQ--ref-00001288-QINU`"' (1) ·
~50% (highly variable) (1)
pregnancy:
None (40) ·
Category C (1) ·
Category C'"`UNIQ--ref-0000008F-QINU`"' (1) ·
Generally considered safe (minimal systemic exposure).<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe; minimal systemic exposure.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; second-line to intranasal corticosteroids or PO loratadine/cetirizine.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 45 results in range #1 to #45.